Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04390763
Title Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

pancreatic adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel

Gemcitabine + Nab-paclitaxel + NIS793 + Spartalizumab

Gemcitabine + Nab-paclitaxel + NIS793

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.